AbCellera Biologics Inc.: directors' dealings · United States · SEC (Form 4)

About AbCellera Biologics Inc.

AbCellera Biologics Inc. is a biotechnology company listed on the NASDAQ market in the United States (United States) under the ticker ABCL. The company focuses on discovering and developing antibody-based medicines using a technology-driven platform that combines microfluidics, data analytics, B-cell screening, and high-throughput discovery workflows to identify therapeutic candidates faster and more efficiently. AbCellera was founded in 2012 by Carl Hansen and colleagues with roots in the University of British Columbia, and its headquarters and core research operations are in Vancouver, Canada, even though its equity is traded in the U.S. public markets. ([investors.abcellera.com](https://investors.abcellera.com/news/news-releases/2018/AbCellera-Celebrates-the-Opening-of-its-New-Research-Facility-and-Corporate-Headquarters/default.aspx?utm_source=openai)) AbCellera’s business model has two main pillars. First, it runs collaborative antibody discovery programs with pharmaceutical and biotech partners. Second, it is building an internal pipeline of proprietary assets to create longer-duration value beyond collaboration fees and milestone economics. For investors, that combination matters: the partnership business helps validate the platform and diversify revenue opportunities, while the internal pipeline provides embedded upside if one or more programs advance successfully through development. The company states that since 2015 it has worked with more than 40 partners across 100+ antibody programs, which underscores the breadth of its platform and the credibility it has established with major life-science customers. ([abcellera.com](https://www.abcellera.com/?utm_source=openai)) Competitively, AbCellera stands out less as a commercial drug seller and more as a discovery infrastructure company. Its strategic edge is its proprietary antibody-finding engine, which is aimed at areas of significant unmet medical need, including endocrinology, women’s health, immunology, oncology, and related therapeutic fields. This makes ABCL a platform biotech rather than a classic pharma manufacturer: the investment case depends on scientific execution, partner traction, and the conversion of discovery capabilities into clinical and eventually commercial assets. That also means the company carries the typical biotech risk profile, including clinical failure, long development timelines, and uncertainty around downstream monetization. ([investors.abcellera.com](https://investors.abcellera.com/news/news-releases/2026/AbCellera-Reports-Full-Year-2025-Business-Results/default.aspx?utm_source=openai)) Recent company updates highlight a business that is increasingly clinical in orientation. In its full-year 2025 results, AbCellera said it ended the year with approximately $700 million in available liquidity, supporting its strategic runway. Management also described 2025 as a year in which the company transitioned into a clinical-stage biotech and expanded its leadership team. One of the notable programs mentioned recently is ABCL635, developed for moderate-to-severe vasomotor symptoms associated with menopause, which illustrates the company’s effort to move platform discoveries into tangible clinical assets. For market participants, AbCellera is best viewed as a U.S.-listed NASDAQ biotechnology company with a Canadian operating base, a strong balance sheet, and a platform story that remains highly dependent on execution across both partnerships and internal pipeline development. ([investors.abcellera.com](https://investors.abcellera.com/news/news-releases/2026/AbCellera-Reports-Full-Year-2025-Business-Results/default.aspx?utm_source=openai))